Class II-associated invariant chain peptide expression on myeloid leukemic blasts predicts poor clinical outcome

Cancer Research

Volumn 64, Issue 16, 2004, Pages 5546-5550

  Chamuleau, Martine E D ^a   Souwer, Yuri ^a,b,c   Van Ham, S Marieke ^b   Zevenbergen, Adri ^a   Westers, Theresia M ^a   Berkhof, Johannes ^a   Meijer, Chris J L M ^a   Van De Loosdrecht, Arjan A ^a   Ossenkoppele, Gert J ^a  

^a VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^b NETHERLANDS CANCER INSTITUTE   (Netherlands)

^c CENTRAL LABORATORY   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

CD4 ANTIGEN; CLASS 2 ASSOCIATED INVARIANT CHAIN PEPTIDE; HLA DM ANTIGEN; HLA DO ANTIGEN; HLA DR ANTIGEN; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2; PEPTIDE DERIVATIVE; UNCLASSIFIED DRUG;

ADOLESCENT; ADULT; AGED; ANTIGEN PRESENTATION; ANTINEOPLASTIC ACTIVITY; ARTICLE; B LYMPHOCYTE; BLAST CELL; BLOOD SAMPLING; BONE MARROW; CANCER PATIENT; CANCER SURVIVAL; CELL SURFACE; CELL TYPE; CONTROLLED STUDY; DISEASE COURSE; FEMALE; FLOW CYTOMETRY; HELPER CELL; HUMAN; HUMAN CELL; HUMAN TISSUE; LEUKEMIA CELL; LYMPHOID CELL; MAJOR CLINICAL STUDY; MALE; MYELOID LEUKEMIA; PREDICTION; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN SECRETION; REGULATORY MECHANISM; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; T LYMPHOCYTE ACTIVATION;

ACUTE DISEASE; ADOLESCENT; ADULT; AGED; ANTIGENS, DIFFERENTIATION, B-LYMPHOCYTE; ANTIGENS, NEOPLASM; FEMALE; FLOW CYTOMETRY; HISTOCOMPATIBILITY ANTIGENS CLASS II; HLA-D ANTIGENS; HUMANS; LEUKEMIA, MYELOID; MALE; MIDDLE AGED; PROGNOSIS;

EID: 4143058279     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-04-1350     Document Type: Article

References (20)

1. Wang RF. The role of MHC class II-restricted tumor antigens and CD4+ T cells in antitumor immunity. Trends Immunol 2001;22:269-76.
2. Lotteau V, Teyton L, Peleraux A, et al. Intracellular transport of class II MHC molecules directed by invariant chain. Nature (Lond) 1990;348:600-5.
3. Romagnoli P, Germain RN. The CLIP region of invariant chain plays a critical role in regulating major histocompatibility complex class II folding, transport, and peptide occupancy. J Exp Med 1994;180:1107-13.
4. Denzin LK, Cresswell P. HLA-DM induces CLIP dissociation from MHC class II alpha beta dimers and facilitates peptide loading. Cell 1995;82:155-65.
5. Martin WD, Hicks GG, Mendiratta SK, Leva HI, Ruley HE, Van Kaer L. H2-M mutant mice are defective in the peptide loading of class II molecules, antigen presentation, and T cell repertoire selection. Cell 1996;84:543-50.
6. van Ham M, van Lith M, Lillemeier B, et al. Modulation of the major histocompatibility complex class II-associated peptide repertoire by human histocompatibility leukocyte antigen (HLA)-DO. J Exp Med 2000;191:1127-36.
7. Chen X, Laur O, Kambayashi T, et al. Regulated expression of human histocompatibility leukocyte antigen (HLA)-DO during antigen-dependent and antigen-independent phases of B cell development. J Exp Med 2002;195:1053-62.
8. Glazier KS, Hake SB, Tobin HM, Chadbum A, Schattner EJ, Denzin LK. Germinal center B cells regulate their capability to present antigen by modulation of HLA-DO. J Exp Med 2002;195:1063-9.
9. Armstrong TD, Clements VK, Martin BK, Ting JP, Ostrand-Rosenberg S. Major histocompatibility complex class II-transfected tumor cells present endogenous antigen and are potent inducers of tumor-specific immunity. Proc Natl Acad Sci USA 1997;94:6886-91.
10. Qiu G, Goodchild J, Humphreys RE, Xu M. Cancer immunotherapy by antisense suppression of Ii protein in MHC-class-II-positive tumor cells. Cancer Immunol Immunother 1999;48:499-506.
11. Qi L, Rojas JM, Ostrand-Rosenberg S. Tumor cells present MHC class II-restricted nuclear and mitochondrial antigens and are the predominant antigen presenting cells in vivo. J Immunol 2000;165:5451-61.
12. Dissanayake SK, Thompson JA, Bosch JJ, et al. Activation of tumor-specific CD4(+) T lymphocytes by major histocompatibility complex class II tumor cell vaccines: a novel cell-based immunotherapy. Cancer Res 2004;64:1867-74.
13. Lowenberg B, Downing JR, Burnett A. Acute myeloid leukemia. N Engl J Med 1999;341:1051-62.
14. Brouwer RE, Zwinderman KH, Kluin-Nelemans HC, Luxemburg-Heijs SA, Willemze R, Falkenburg JH. Expression and induction of costimulatory and adhesion molecules on acute myeloid leukemic cells: implications for adoptive immunotherapy. Exp Hematol 2000;28:161-8.
15. Alfonso C, Karlsson L. Nonclassical MHC class II molecules. Annu Rev Immunol 2000;18:113-42.
16. Tolosa E, Li W, Yasuda Y et al. Cathepsin V is involved in the degradation of invariant chain in human thymus and is overexpressed in myasthenia gravis. J Clin Investig 2003;112:517-26.
17. Riberdy JM, Cresswell P. The antigen-processing mutant T2 suggests a role for MHC-linked genes in class II antigen presentation. J Immunol 1992;148:2586-90.
18. Sette A, Southwood S, Miller J, Appella E. Binding of major histocompatibility complex class II to the invariant chain-derived peptide, CLIP, is regulated by allelic polymorphism in class II. J Exp Med 1995;181:677-83.
19. Osman Y, Takahashi M, Zheng Z, et al. Dendritic cells stimulate the expansion of PML-RAR alpha specific cytotoxic T-lymphocytes: its applicability for antileukemia immunotherapy. J Exp Clin Cancer Res 1999;18:485-92.
20. Roucard C, Thomas C, Pasquier MA, et al. In vivo and in vitro modulation of HLA-DM and HLA-DO is induced by B lymphocyte activation. J Immunol 2001;167:6849-58.